Cover Image

Comparison of complement component C3 level with bacterial infections in decompensated liver disease patients in a tertiary care hospital

Rajeswari Jayakumar*, Thasneem Banu S., Venkatesh K. G.


Bacterial infections are more common in decompensated liver disease patients with low level of complement component 3 and causes 30%-50% of deaths. Therefore, this study done to determine the various bacterial agents causing infections in decompensated liver disease patients and to estimate the level of C3 component of complement by Enzyme linked immunosorbent assay. A prospective study was conducted over a period of one year in Madras Medical College. Ascitic fluid, urine, sputum, wound swab blood and serum were collected. All the samples were processed through Gram’s stain and culture. The organisms were identified by standard protocols and antibiotic susceptibility testing and to correlate the bacterial infections with complement C3 level by ELISA. Out of 100 samples, culture positivity seen in 54[54%]. In 54 culture, positive isolates, 41(76%) were Gram Negative bacilli and 13 (24%) were Gram Positive cocci. Among Gram negative bacilli, Escherichia coli and in Gram positive cocci, Staphylococcus aureus was the most common isolates. The most common infections were spontaneous bacterial peritonitis [29.6%] followed by urinary tract infections [26%], pneumonia [20.3%], Spontaneous bacteraemia [16.7%], and skin and soft-tissue infections [7.4%]. Out of 100patients, 66(66%) patients had low complement component C3 level. Of which 42(63.6%) patients were cultures positive and 24(36.4%) were culture negative. 34(34%) patients had normal complement component C3 level, of which 29 (85.3%) were culture negative and 5 (14.7%) were culture positive.


Complement component C3; Decompensated liver disease; spontaneous bacterial peritonitis; Escherichia coli; Staphylococcus aureus; Enzyme linked immunosorbent assay

Full Text:



Robbins and Cotran. Pathologic basis of diseases – 8th Edition. Sounder, Elseive publication

V.A. Sevastianos, S.P. Dourakis. Pathogenesis, diagnosis and therapy of Infections complicating patients with chronic liver disease- Review.

Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I Diagnosis and evaluation. Am Fam Physician. 2006;74:756–762.

Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290:228–237.

Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi Pagliaro . Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. World J Hepatol. 2006 January; 44(1):217-231.

Harrison’s principle of Internal medicine – 18th Edition.2592- 2602

Garcia –Tsao G, Wiest R. Gut microflora in the pathogenesis of the complication of cirrhosis. Best pract Res Clinical GE 2004;18: 353-372

Christou L, Pappas G, Falagas ME. Bacterial Infection related morbidity and mortality in cirrhosis. American Journal of Gastroenterology 2007; 102: 1510-1517

Fierer J, Fineley F. Deficient serum bactericidal activity against E.coli in patients with cirrhosis of the liver. Journal of Clinical Invest 1979; 63: 912 – 921

Hassner A, Kletter Y, Shlag D, et al. Impaired monocyte function in liver cirrhosis. BMJ 1981;282: 1262 – 1263

Garcia – Gonnzalez M, Boixeda D, Herraro D, et al. Effect of granulocyte. Macrophage colony stimulating factor on leukocyte function in cirrhosis. Journal of Gastroenterology 1993; 105: 527 – 531.

Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rhodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology. 1984; 4:53–8.

Bolognesi M, Merkel C, Bianco S, Angeli P, et al. Clinical significance of the evaluation of hepatic Reticuloendothelial cell removal capacity in patients with cirrhosis. Hepatology 1994; 19: 628-638.

Dupeyron C, Campillo SB, Mangeney N, Richardet JP, Leluan G. Carriage of Staphylococcus aureus and of gram-negative bacilli resistant to third-generation cephalosporins in cirrhotic patients: a prospective assessment of hospital-acquired infections..infect Contol Hosp Epidemiol.2001 jul:22(7):427-232. 8. Papp M, Farkas A, Udvardy M, Tornai. Bacterial infections in liver cirrhosis.Orv 2007 March 4;148(9):387-95.

Swartz ML, Pasternack MS. Cellulitis and superficial infections. Prin Pract Inf Dis. 1999;88:34–37.

Rooby Erachamveettil Hamza, Mashhood Padincharepurathu Villyoth, George Peter, Deni Joseph, Chethan Govindaraju, Devang Chandrakanth Tank, Sreejaya Sreesh, Premalatha Narayanan, Kattoor Ramakrishnan Vinayakumar. Risk factors of cellulitis in cirrhosis and antibiotic prophylaxis in preventing recurrence. Annals of Gastroenterology (2014) 27, 1-6.

Alper, C.A., Johnson, A.M., Birtch, A.G., and Moore, F.D- Human C3: Evidence for the liver as the primary site for synthesis .1969; 163:286-288.

Colten H.R. Oncogeny of the Human complement component system: In vitro biosynthesis of individual complement component by fetal tissues. Journal of clini. invest.1972; 51:725-730.

Wilson, C.B. and Dixon, F.T .Antigen quantitation in experimental immune complex glomerulonephritis.(Acute serum sickness.). Journal of Immunology.1970;105:279-290.

Rajkovic and R.Williams, “Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis,” Hepatology,vol.6,no.2,pp. 252–262, 1986.

Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012: S1– S12.

Arvaniti V, D'Amcio G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246–1256.

Mathurin S, Chapelet A, Spanevello V, Sayago G, Balparda C, Virga E, Beraudo N, Bartolomeo M. Infections in hospitalized patients with cirrhosis.2009;69(2):229-38.

C Homann, K Varming, K H0gasen, T E Mollnes, N Graudal, A C Thomsen, P Garred Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997;44: 544-549.

Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S,Colloredo-Mels G, Corigliano P, Fornaciari G, Marenco G, Pistarà R, Salvagnini M, Sangiovanni A. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001 Jan-Feb;33(1):41-8.

Puneeta Tandon, M.D. Guadalupe Garcia – Tsao. Bacterial infections, sepsis and multi organ failure in cirrhosis.W. R. Caly and E. Strauss, “A prospective study of bacterial infections in patients with cirrhosis,” Journal of Hepatology, vol. 18, no.3,pp. 353–358, 1993 .

Anthony P.P. et al., World Health Organization.Journal of Clinical Pathology 31:395,1978

Mohan P1, Ramu B, Bhaskar E, Venkataraman J.Prevalence and risk factors for bacterial skin infection and mortality in cirrhosis.Ann. Hepatology 2011 Jan-Mar;10(1):15-20.

Mustafa G, Khan M, Alam K, Rahman S, Ahmad N, Alam S, Ahmed S. Study on ascitic fluid complement 3 level in cirrhotic patients with spontaneous bacterial peritonitis and without spontaneous bacterial peritonitis. Hepatogastroenterology. 2007 Oct-Nov;54(79):1905-7.)

Amany Talaat Kamal, Eman Nagib Osman, Rasha Youssef Shahin Role of ascitic fluid C3 in spontaneous bacterial peritonitis.

C. Guarner and B. A. Runyon, “Macrophage function in cirrhosis and the risk of bacterial infection,” Hepatology, vol. 22, no.1,pp. 367–369, 1995.



  • There are currently no refbacks.

Copyright (c) 2016 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.